Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Diagnostic test for personalised statin treatment

Oxford, UK, 18th November 2010 Two recent studies at Oxford have highlighted the potential healthcare and economic benefits of personalising statin treatment based on a patientís genetic risk to statin-induced myopathy. Researchers at Oxford have identified a biomarker which is highly associated with statin-induced myopathy that could form the basis of a diagnostic test for this side effect of statin use. Isis Innovation has filed a patent application based on this discovery and is looking for commercial partners to develop this test.

Myopathy is a rare side effect of statin use that results in muscle pain and weakness. Researchers at the Clinical Trial Service Unit at the University of Oxford have previously identified a biomarker that is highly associated with statin-induced myopathy, as reported in The New England Journal of Medicine in 2008[1],[2].

The new studies[3], published by the same group at Oxford in The Lancet[4],[5], demonstrate the potential healthcare benefits of intensive statin use in people at risk of heart disease. This treatment resulted in a 15% further reduction in cardiovascular events and deaths compared to standard statin therapy. However, raising blood concentrations with higher statin doses, particularly with generic statins (such as Simvastatin), also increases the rate of myopathy. The authors advise that it may be safer to use low doses of more potent statins (such as Lipitor or Crestor) rather than to increase the dose of less potent statins (such as Simvastatin) in individuals at risk of myopathy.

Testing for the Oxford biomarker would allow an individualís statin treatment to be personalised based on their genetic risk of myopathy. This offers both potential cost- savings and healthcare benefits by identifying individuals who could safely benefit from low-cost generic statins (such as Simvastatin) versus individuals who could benefit from the newer more potent, but expensive, branded statins.

Industry enquiries to:

Andy Self

Product Manager, Isis Innovation Ltd

T: 01865 614442

Media enquiries to:

Simon Gray

Marketing & Communications Manager, Isis Innovation Ltd

T: 01865 614428

~ ENDS ~

About Isis Innovation

Isis Innovation is the University of Oxford's technology transfer company and manages the University's intellectual property portfolio, working with University researchers on identifying, protecting and marketing technologies through licensing, spin-out company formation and material sales. Isis files on average one new patent application each week, has concluded over 500 technology licensing agreements, and established 68 new spin-out companies from Oxford since 1997. Isis also manages Oxford University Consulting, which arranges consulting services providing clients access to the world-class expertise of the University's academics to enhance innovative capability. Last year OUC arranged over 150 consulting deals. Isis has established a separate business division, Isis Enterprise, offering consulting expertise and advice in technology transfer and open innovation to university, government and industrial clients around the world. Isis was founded in 1987 and is today one of the world's leading technology transfer and innovation management companies.

Publisher Contact Information:

Isis Innovation
+44 1865 614442

Company profile of Isis Innovation
Past press releases of Isis Innovation.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 21€87.0MInternet services
Feb 21€18.0MInternet commerce
Feb 20€4.3MSoftware development
Feb 19€0.4MInternet commerce
Feb 19€8.4MMedical devices
Feb 18€25.0MBiotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.